JP2012527218A - Mycoplasmahyopneumoniaeの温度感受性ワクチン株およびその使用 - Google Patents
Mycoplasmahyopneumoniaeの温度感受性ワクチン株およびその使用 Download PDFInfo
- Publication number
- JP2012527218A JP2012527218A JP2012511093A JP2012511093A JP2012527218A JP 2012527218 A JP2012527218 A JP 2012527218A JP 2012511093 A JP2012511093 A JP 2012511093A JP 2012511093 A JP2012511093 A JP 2012511093A JP 2012527218 A JP2012527218 A JP 2012527218A
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- mycoplasma hyopneumoniae
- strain
- mycoplasma
- hyopneumoniae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 93
- 241000204045 Mycoplasma hyopneumoniae Species 0.000 title claims abstract description 63
- 230000035772 mutation Effects 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 19
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 19
- 230000002238 attenuated effect Effects 0.000 claims abstract description 18
- 238000005259 measurement Methods 0.000 claims abstract description 6
- 241000282887 Suidae Species 0.000 claims description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 201000010099 disease Diseases 0.000 claims description 28
- 241000282898 Sus scrofa Species 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 238000000338 in vitro Methods 0.000 claims description 9
- 238000002703 mutagenesis Methods 0.000 claims description 9
- 231100000350 mutagenesis Toxicity 0.000 claims description 9
- 230000001681 protective effect Effects 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 8
- 206010035664 Pneumonia Diseases 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 8
- 239000000443 aerosol Substances 0.000 claims description 8
- 239000012678 infectious agent Substances 0.000 claims description 8
- 241000204003 Mycoplasmatales Species 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 201000008235 Mycoplasma pneumoniae pneumonia Diseases 0.000 claims description 6
- 230000036039 immunity Effects 0.000 claims description 6
- 208000001572 Mycoplasma Pneumonia Diseases 0.000 claims description 4
- 210000002345 respiratory system Anatomy 0.000 claims description 4
- 241000233866 Fungi Species 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 230000003053 immunization Effects 0.000 claims description 3
- 244000045947 parasite Species 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 241000204031 Mycoplasma Species 0.000 description 16
- 230000003902 lesion Effects 0.000 description 15
- 210000004072 lung Anatomy 0.000 description 14
- 238000002255 vaccination Methods 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- 238000010222 PCR analysis Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 206010041232 sneezing Diseases 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000004584 weight gain Effects 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 4
- 238000011887 Necropsy Methods 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000001331 nose Anatomy 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 210000003437 trachea Anatomy 0.000 description 4
- 241000271566 Aves Species 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000006538 friis medium Substances 0.000 description 3
- 229940031551 inactivated vaccine Drugs 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000008203 tachypnea Diseases 0.000 description 3
- 206010043089 tachypnoea Diseases 0.000 description 3
- 241000588807 Bordetella Species 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 206010035724 Pneumonia mycoplasmal Diseases 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 229940031567 attenuated vaccine Drugs 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 210000004081 cilia Anatomy 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 229940124452 immunizing agent Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000272478 Aquila Species 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001529548 Megasphaera cerevisiae Species 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 108010020764 Transposases Proteins 0.000 description 1
- 101710108495 Ts19 Proteins 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- WXNRAKRZUCLRBP-UHFFFAOYSA-N avridine Chemical compound CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCCCCCCCCCCCCCCCCC WXNRAKRZUCLRBP-UHFFFAOYSA-N 0.000 description 1
- 229950010555 avridine Drugs 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940073505 ethyl vanillin Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007108 local immune response Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- -1 parabens Chemical compound 0.000 description 1
- 229940090668 parachlorophenol Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 238000011886 postmortem examination Methods 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012770 revaccination Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940044609 sulfur dioxide Drugs 0.000 description 1
- 235000010269 sulphur dioxide Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/36—Adaptation or attenuation of cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/35—Mycoplasma
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/87—Mycoplasma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
【選択図】なし
Description
オーストラリアのMycoplasma hyopneumoniae(マイコプラズマ・ハイオニューモニエ)分離株LKRは、典型的な流行性肺炎疾患を呈するブタの肺の、屠殺場検体である(LloydおよびEtheridge(1981)、J.Comp.Path. 91:77−83)。この分離株を培養し、南オーストラリア州のUniversity of Adelaide(アデレード大学)のMycoplasma reference culture collection(マイコプラズマ・リファレンス・カルチャー・コレクション)で保存した。その後、この分離株の培養物は、ビクトリア州のUniversity of Melbourne(メルボルン大学)のMycoplasma group(マイコプラズマグループ)によって得られた。
ワクチンを調製するために、ts19の培養物を、酸による色調変化が観察されるまで、フェノールレッド(pH指示薬)を含有する改変Friis培地中、33℃で成長させた。96穴のマイクロタイタープレートを使用して、ワクチンを改変Friis培地中で滴定した。マイクロタイタープレートの12列のうちの最初の10列にわたって、一連の10倍希釈を行った。最後の2レーンは接種しないまま残り、培地のみの(陰性)対照としての役割を果たした。6つまでのマイクロタイタープレートを、各滴定で使用した。
ts19ワクチン株の安全性プロファイルを評価するために、研究を行った。この研究デザインは、Mycoplasma(マイコプラズマ)を含まないブタ群から得た6週齢のブタの使用を必要とした。この研究は、CSIRO(Commonwealth Serum Industry Research Organisation(オーストラリア連邦科学産業研究機構)、オーストラリア、ビクトリア州、ウェロビー(Werribee)で、PC2バイオセキュリティーレベルのもとで行った。合計20匹のブタを、各10匹のブタの2つの群に無作為に割り当てた(表2を参照)。
ts19ワクチン株の有効性を評価するために、研究を行った。この研究デザインは、Mycoplasma(マイコプラズマ)を含まないブタ群から得た6週齢のブタの使用を必要とした。この研究は、CSIRO(Commonwealth Serum Industry Research Organisation(オーストラリア連邦科学産業研究機構)、オーストラリア、ビクトリア州、ウェロビー(Werribee)で、PC2バイオセキュリティーレベルのもとで行った。合計56匹のブタを、各ワクチン接種を受けた群について12匹のブタの3群および対照群の各々について10匹のブタに無作為に割り当てた(表3を参照)。
4つの異なる用量におけるts19ワクチン株の有効性を評価するために、研究を行った。この研究デザインは、3〜4週齢のspfブタの使用を必要とした。この研究は、Centro de Nacional de Servicios de Diagnostico en Salud Animal(国立家畜衛生診断サービスセンター)、CENASA) − メキシコ、テカマック(Tecamac)にある政府機関の試験施設 − にあるPC2施設の中で行った。合計70匹のブタを、各々10匹のブタを含む7つの群に無作為に割り当てた(表4)。
Claims (15)
- 表1に列挙されている遺伝子のうちの少なくとも1つにおいて変異を含むMycoplasma hyopneumoniaeワクチン株。
- 温度感受性でありかつ弱毒化されている、National Measurements Institute(オーストラリア)に受入番号NM04/41259で寄託されたMycoplasma hyopneumoniaeワクチン株。
- 請求項1または請求項2に記載の株を製造する方法であって、Mycoplasma hyopneumoniaeの適切な出発株を化学的変異生成にかける工程と、連続的なインビトロでの継代後に生存可能であり続ける温度感受性変異体を選択する工程と、を含む方法。
- 前記出発株は、Mycoplasma hyopneumoniae株LKR P3である、請求項3に記載の方法。
- ワクチン組成物であって、請求項1もしくは請求項2に記載のMycoplasma hyopneumoniae株、または請求項3に記載の方法によって調製されたMycoplasma hyopneumoniae株と、担体と、任意に佐剤と,および/または任意に少なくとも1つの付加的な感染病原体とを含み、免疫量の前記ワクチンは、Mycoplasma hyopneumoniaeによって引き起こされる疾患に対する防御免疫を誘発することができる、ワクチン組成物。
- 前記感染病原体はウイルス、細菌、真菌または寄生生物である、請求項5に記載のワクチン組成物。
- 気道への投与のために製剤化されている、請求項5または請求項6に記載のワクチン組成物。
- エアロゾル製剤の状態の、請求項5または請求項6に記載のワクチン組成物。
- ブタ類動物における、Mycoplasma hyopneumoniaeによって引き起こされる疾患を防止するための方法であって、免疫量の、請求項5から請求項8のいずれか1項に記載のワクチン組成物を前記ブタ類動物に投与することを含む、方法。
- ブタ類動物における、Mycoplasma hyopneumoniaeによって引き起こされる疾患を防止するための、請求項5から請求項8のいずれか1項に記載のワクチン。
- 前記ワクチンは気道に投与される、請求項9に記載の方法。
- 前記ワクチンは、吸入によって、鼻腔内に、またはエアロゾルによって投与される、請求項9に記載の方法。
- 請求項5に記載のワクチンを製造する方法であって、請求項1または請求項2に記載のMycoplasma hyopneumoniae株を担体、任意に佐剤および/または任意に少なくとも1つの付加的な感染病原体と合わせる工程と含む、方法。
- ブタ類動物における、Mycoplasma hyopneumoniaeによって引き起こされる疾患を防止するための医薬の製造における、請求項1または請求項2に記載のMycoplasma hyopneumoniae株の使用。
- Mycoplasma hyopneumoniaeによって引き起こされる前記疾患は流行性肺炎またはブタマイコプラズマ性肺炎である、請求項5に記載のワクチン、請求項9に記載の方法、または請求項10に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2009902255A AU2009902255A0 (en) | 2009-05-19 | Bacterial strain, vaccine and uses thereof | |
AU2009902255 | 2009-05-19 | ||
PCT/AU2010/000590 WO2010132932A1 (en) | 2009-05-19 | 2010-05-19 | A temperature sensitive vaccine strain of mycoplasma hyopneumoniae and uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012527218A true JP2012527218A (ja) | 2012-11-08 |
JP2012527218A5 JP2012527218A5 (ja) | 2013-06-20 |
JP5744852B2 JP5744852B2 (ja) | 2015-07-08 |
Family
ID=43125658
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012511093A Active JP5744852B2 (ja) | 2009-05-19 | 2010-05-19 | Mycoplasmahyopneumoniaeの温度感受性ワクチン株およびその使用 |
Country Status (17)
Country | Link |
---|---|
US (1) | US8524252B2 (ja) |
EP (1) | EP2453913B1 (ja) |
JP (1) | JP5744852B2 (ja) |
KR (1) | KR101734590B1 (ja) |
CN (1) | CN102458462B (ja) |
AU (1) | AU2010251761B2 (ja) |
BR (1) | BRPI1010679B1 (ja) |
CA (1) | CA2762587C (ja) |
CL (1) | CL2011002923A1 (ja) |
DK (1) | DK2453913T3 (ja) |
EA (1) | EA021102B1 (ja) |
ES (1) | ES2579935T3 (ja) |
MX (1) | MX2011012362A (ja) |
NZ (1) | NZ596722A (ja) |
PE (1) | PE20120909A1 (ja) |
WO (1) | WO2010132932A1 (ja) |
ZA (1) | ZA201109185B (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2799732A1 (en) | 2010-05-19 | 2011-11-24 | Bioproperties Pty Ltd | Methods relating to an attenuated mycoplasma |
CN104685057B (zh) * | 2012-07-10 | 2019-04-16 | 海博莱科学有限公司 | 用于转化猪肺炎支原体的载体,转化的猪肺炎支原体菌株及其用途 |
EP2684959A1 (en) | 2012-07-10 | 2014-01-15 | Laboratorios Hipra, S.A. | Vectors for transforming Mycoplasma hyopneumoniae, transformed M.hyopneumoniae strains, and use thereof |
CN104968365B (zh) | 2012-12-28 | 2018-04-03 | 勃林格殷格翰动物保健有限公司 | 支原体疫苗的制备方法 |
KR102355614B1 (ko) | 2012-12-28 | 2022-01-27 | 베링거잉겔하임베트메디카게엠베하 | 마이코플라스마 항원을 포함하는 면역원성 조성물 |
EP2913947B1 (en) * | 2014-02-27 | 2019-11-27 | ADVA Optical Networking SE | Passive optical network and optical line terminal |
KR20160099223A (ko) * | 2015-02-12 | 2016-08-22 | 강원대학교산학협력단 | 마이코플라스마 하이오뉴모니애 박테린 백신 및 이의 제조방법 |
US10071149B2 (en) | 2016-05-03 | 2018-09-11 | Brigham Young University | Temperature sensitive multivalent Bordetella avium vaccines |
CN113278575B (zh) * | 2021-07-13 | 2021-12-31 | 南华大学 | 一种肺炎支原体减毒突变株及应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004505096A (ja) * | 2000-07-27 | 2004-02-19 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | Mycoplasmahyopneumoniaeに対する温度感受性の生ワクチン |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPN178995A0 (en) * | 1995-03-16 | 1995-04-13 | University Of Melbourne, The | Antigen composition |
CN1100871C (zh) * | 1999-06-25 | 2003-02-05 | 江苏省农业科学院畜牧兽医研究所 | 猪肺炎支原体克隆致弱株 |
US6673567B2 (en) * | 2000-03-23 | 2004-01-06 | E. I. Du Pont De Nemours And Company | Method of determination of gene function |
MY129765A (en) * | 2000-12-19 | 2007-04-30 | Wyeth Corp | Improved mycoplasma hyopneumoniae bacterin vaccine |
JP2004537543A (ja) * | 2001-07-02 | 2004-12-16 | ファイザー・プロダクツ・インク | マイコプラズマ・ハイオニューモニエ・ワクチンおよび牛におけるマイコプラズマ・ボビス低減方法 |
US7691368B2 (en) * | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
EP1991262A4 (en) * | 2006-03-03 | 2009-11-04 | Merial Ltd | MYCOPLASMA HYOPNEUMONIAE VACCINE |
RU2489164C9 (ru) * | 2007-11-06 | 2014-01-20 | ВАЙЕТ ЭлЭлСи | АВИРУЛЕНТНАЯ АДЪЮВАНТНАЯ ЖИВАЯ ВАКЦИНА ПРОТИВ Mycoplasma hyopneumoniae |
PL2475384T3 (pl) * | 2009-09-10 | 2017-02-28 | Merial, Inc. | Nowe formulacje szczepionek obejmujące adiuwanty zawierające saponiny |
US9324223B2 (en) | 2012-06-08 | 2016-04-26 | 3M Innovative Properties Company | Electronic monitoring home unit and installation methods |
-
2010
- 2010-05-19 EP EP10777221.2A patent/EP2453913B1/en active Active
- 2010-05-19 DK DK10777221.2T patent/DK2453913T3/en active
- 2010-05-19 CA CA2762587A patent/CA2762587C/en active Active
- 2010-05-19 BR BRPI1010679-0A patent/BRPI1010679B1/pt active IP Right Grant
- 2010-05-19 WO PCT/AU2010/000590 patent/WO2010132932A1/en active Application Filing
- 2010-05-19 MX MX2011012362A patent/MX2011012362A/es active IP Right Grant
- 2010-05-19 NZ NZ596722A patent/NZ596722A/xx unknown
- 2010-05-19 US US13/321,662 patent/US8524252B2/en active Active
- 2010-05-19 PE PE2011001988A patent/PE20120909A1/es not_active Application Discontinuation
- 2010-05-19 ES ES10777221.2T patent/ES2579935T3/es active Active
- 2010-05-19 AU AU2010251761A patent/AU2010251761B2/en active Active
- 2010-05-19 CN CN201080031403.2A patent/CN102458462B/zh active Active
- 2010-05-19 JP JP2012511093A patent/JP5744852B2/ja active Active
- 2010-05-19 EA EA201190311A patent/EA021102B1/ru not_active IP Right Cessation
- 2010-05-19 KR KR1020117030155A patent/KR101734590B1/ko active IP Right Grant
-
2011
- 2011-11-18 CL CL2011002923A patent/CL2011002923A1/es unknown
- 2011-12-13 ZA ZA2011/09185A patent/ZA201109185B/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004505096A (ja) * | 2000-07-27 | 2004-02-19 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | Mycoplasmahyopneumoniaeに対する温度感受性の生ワクチン |
Non-Patent Citations (3)
Title |
---|
JPN6014037616; J.Comp.Pathol.,1981,91(1),p.77-83 * |
JPN6014037617; J.Comp.Pathol.,1984,94(1),p.1-8 * |
JPN6014037620; Aust.Vet.J.,1990,67(5),p.159-65 * |
Also Published As
Publication number | Publication date |
---|---|
MX2011012362A (es) | 2012-04-19 |
CN102458462B (zh) | 2014-03-19 |
EA021102B1 (ru) | 2015-04-30 |
KR20120016282A (ko) | 2012-02-23 |
BRPI1010679A2 (pt) | 2017-07-18 |
CN102458462A (zh) | 2012-05-16 |
US8524252B2 (en) | 2013-09-03 |
EP2453913B1 (en) | 2016-06-22 |
KR101734590B1 (ko) | 2017-05-11 |
CL2011002923A1 (es) | 2012-08-31 |
ZA201109185B (en) | 2012-09-26 |
AU2010251761B2 (en) | 2014-10-09 |
CA2762587C (en) | 2017-11-28 |
DK2453913T3 (en) | 2016-07-25 |
PE20120909A1 (es) | 2012-08-19 |
US20120135040A1 (en) | 2012-05-31 |
EA201190311A1 (ru) | 2012-06-29 |
NZ596722A (en) | 2013-08-30 |
AU2010251761A1 (en) | 2011-12-22 |
WO2010132932A1 (en) | 2010-11-25 |
ES2579935T3 (es) | 2016-08-17 |
EP2453913A1 (en) | 2012-05-23 |
EP2453913A4 (en) | 2013-10-30 |
CA2762587A1 (en) | 2010-11-25 |
JP5744852B2 (ja) | 2015-07-08 |
BRPI1010679B1 (pt) | 2020-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5744852B2 (ja) | Mycoplasmahyopneumoniaeの温度感受性ワクチン株およびその使用 | |
Nicholas et al. | An experimental vaccine for calf pneumonia caused by Mycoplasma bovis: clinical, cultural, serological and pathological findings | |
JP5789897B2 (ja) | マイコプラズマ・ボビス ワクチン | |
JP2013223511A6 (ja) | マイコプラズマ・ボビス ワクチン | |
JP2011500093A6 (ja) | マイコプラズマ・ボビス ワクチン | |
JPH07206705A (ja) | 生インオボ(in ovo)ワクチン | |
US20140178435A1 (en) | Vaccine comprising inactivated cells of haemophilus parasuis bacteria of serotype 5 | |
KR20030036647A (ko) | 마이코플라스마 하이오뉴모니에에 대한 온도-감수성 생 백신 | |
JP5745731B2 (ja) | サルモネラワクチン | |
EP2389433B1 (en) | Mycoplasma gallisepticum formulation | |
EP2962696A1 (en) | Novel veterinary vaccine compositions for use in the treatment of infectious diseases caused by or associated with Pasteurellaceae family bacteria | |
RU2761966C2 (ru) | Пероральная вакцина против респираторного заболевания жвачных животных, содержащая поливинилпирролидон | |
US20170072042A1 (en) | Salmonella choleraesuis-salmonella typhimurium vaccines | |
AU2008318793B2 (en) | Mycoplasma bovis vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130425 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130425 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130522 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140902 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141128 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150331 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150430 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5744852 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |